RxDoctor Payments Data

James Cook, MD

Neurology · Abington, PANPI 1679677074

Payments from drug & device makers

$5,001in general payments, 2019–2025

Across 249 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$957
  • Argenx US, Inc.$471
  • Teva Pharmaceuticals USA, Inc.$264
  • Lundbeck LLC$196
  • Medtronic$188
  • AstraZeneca$176
  • plus $3K from 47 others

What the payments were for

  • Speaking & faculty fees$1383%
  • Food & beverage$4,75195%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,001 in reported general payments places this provider in the 65th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$359,025
Medicare patients
401
Services billed
34,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5040$423,692
OctagamImmun Globg(Igg)/Malt/Iga Ov5014$341,665
PanzygaImmun Glob G(Igg)-Ifas/Glycine11$142,714
IngrezzaValbenazine Tosylate14$116,892
NeuproRotigotine15$38,595
Carbidopa-LevodopaCarbidopa/Levodopa276$11,221
QuliptaAtogepant11$10,576
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone17$10,218
Rasagiline Mesylate35$9,752
Entacapone20$5,530
AmantadineAmantadine Hcl40$3,790
Propranolol Hcl ErPropranolol Hcl42$3,016
Carbidopa-Levodopa ErCarbidopa/Levodopa56$2,508
Propranolol Hcl61$2,157
Selegiline Hcl13$1,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Panzyga$21$484,38025 claims
CSL BehringPrivigen$92$423,69240 claims
Neurocrine Biosciences, Inc.Ingrezza$56$116,89214 claims
UCB, Inc.Neupro$94$38,59515 claims
AbbVieQulipta$957$10,57611 claims
Upsher-smith Laboratories LLCTopiramate$13$76338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →